Diagnosis and Treatment of Non–Small Cell Lung Cancer: From Where We Have Been to Where We Are Going

Sandip P. Patel, MD

November 29, 2021

Sandip Patel, MD, describes a changing oncologic landscape in which treatment of non–small cell lung cancer (NSCLC) has given rise to new modes and values. Personalized medicine, including molecular testing at the diagnostic stage and targeted and immunotherapies at the treatment stage, have dramatically increased overall survival rates and promise to increase them further as novel forms of therapy follow in the wake of these recent advances, shifting the gaze from "where we've been" to "where we're going."

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Diagnosis and Treatment of Non–Small Cell Lung Cancer: From Where We Have Been to Where We Are Going - Medscape - Nov 29, 2021.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.